Subscribe or Manage Preferences

Rx Profiler

Sarilumab (Kevzara) is a novel interleukin (IL)-6 receptor inhibitor that was approved by the US Food and Drug Administration (FDA) on May 22, 2017, for the treatment of adults with moderately or severely active RA who have had an inadequate response or intolerance to 1 or more DMARDs.

Results 1 - 1 of 1
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology